Google
Trusted Resources: News & Events
Latest announcements and gatherings
Fighting sickle cell disease by looking back to babyhood
Fast-track research focused on developing a new gene-modifying sickle cell disease treatment at the Medical University of South Carolina could lead to human clinical trials in as few as three years.
Patrick Woster, the SmartState endowed chair in medicinal chemistry at MUSC, said the project takes aim at the enzyme lysine-specific demethylase 1, or LSD 1. That enzyme is part of the biological process that makes mutated hemoglobin, leading to sickle-shaped blood cells. They stick together, causing extremely painful and dangerous blood flow problems. Inhibiting LSD 1, making it less effective, could turn an important gene back on again and keep sickle-shaped cells from sticking together.
+myBinderRelated Content
-
CIRM and NHLBI Collaborating to Fund Cell and Gene Therapies for Sickle Cell DiseaseThe California Institute for Regenerativ...
-
Off-label prescription of hydroxycarbamide (hydroxyurea, HU) for severe anemia: preliminary results from European no...HU is licensed in Europe in the preventi...
-
Big Jump in Success for Sickle Cell TransplantsDoubling the dose of total-body irradiat...
-
Sickle Cell Anemia Explanationhttps://www.youtube.com/watch?v=3ar56G4N...
-
American Society of Hematology 2020 Guidelines for Sickle Cell Disease: Management of Acute and Chronic PainObjective: These evidence-based guideli...
-
Novartis acquires US pharma research firm Selexys PharmaceuticalsSwiss-based pharmaceuticals giant Novart...
-
ASH launches sickle cell disease clinical trials network to accelerate therapy developmentASH launched a clinical trials network d...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.